A TRIAL OF INDIVIDUAL DOSE INTENSITY AND RELATIVE PERFORMANCE-FACTORS IN TEGAFUR MAINTENANCE CHEMOTHERAPY FOR HEAD AND NECK-CANCER

被引：0
|
作者：
SAWAKI, S
WATANABE, H
SHIN, T
KUBOTA, T
KOMIYAMA, S
UMEZAKI, T
NAHM, I
机构：
[1] SAGA MED SCH,DEPT OTOLARNYGOL HEAD & NECK SURG,SAGA 849,JAPAN
[2] YOKOHAMA CITY UNIV,SCH MED,DEPT OTOLARYNGOL,YOKOHAMA 236,JAPAN
[3] SHOWA UNIV,FUJIGAOKA HOSP,DEPT OTOLARYNGOL,YOKOHAMA 227,JAPAN
[4] KYUSHU UNIV,FAC MED,DEPT OTOLARYNGOL,FUKUOKA 812,JAPAN
来源：
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY | 1993年 / 250卷 / 07期
关键词：
HEAD AND NECK CANCER; CHEMOTHERAPY; INDIVIDUAL DOSE INTENSITY; RELATIVES PERFORMANCE;
D O I：
暂无
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Tegafur (Sunfural-S), as masked compound of a 5-fluorouracil derivative, was administered orally as a maintenance chemotherapeutic agent at a dose of 600 mg/day in 98 cases of head and neck epithelial cancer. The effectiveness of the drug was evaluated by a statistical method involving two formulae: individual dose intensity (IDI) and relative performance (RP). When comparing patients rated above a reference IDI value of 1.0 with those rated below 1.0, it was not possible to predict patient survival or tumor-free rates. In contrast, the value of the RP did show such a correlation. These findings support the effectiveness of Tegafur as a maintenance chemotherapeutic treatment for head and neck cancer patients.
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [21] Risk Factors of anemia in head and neck cancer patients undergoing chemotherapy with high-dose cisplatin
    Kurnianda, Johan
    Wiyadi, Nugroho
    Wulaningsih, Wahyu
    MEDICAL JOURNAL OF INDONESIA, 2008, 17 (04) : 248 - 254
  • [22] COMBINED RADIOTHERAPY AND CHEMOTHERAPY WITH BLEOMYCIN AND METHOTREXATE FOR ADVANCED INOPERABLE HEAD AND NECK-CANCER - UPDATE OF A NORTHERN CALIFORNIA ONCOLOGY GROUP RANDOMIZED TRIAL
    FU, KK
    PHILLIPS, TL
    SILVERBERG, IJ
    JACOBS, C
    GOFFINET, DR
    CHUN, C
    FRIEDMAN, MA
    KOHLER, M
    MCWHIRTER, K
    CARTER, SK
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1410 - 1418
  • [23] TIME-DOSE RELATIONSHIP FOR LOCAL TUMOR-CONTROL FOLLOWING ALTERNATE WEEK CONCOMITANT RADIATION AND CHEMOTHERAPY OF ADVANCED HEAD AND NECK-CANCER
    WONG, WW
    MICK, R
    HARAF, DJ
    WEICHSELBAUM, RR
    VOKES, EE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01): : 153 - 162
  • [24] Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial -: Results of a retrospective study
    Jackisch, C
    Jaber, M
    Burkamp, U
    Rody, A
    Rösel, S
    Raab, G
    Koch, OM
    Dame, W
    Gropp, C
    Gleumes, L
    Eiermann, W
    Schneider, HPG
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2003, 63 (04) : 333 - 341
  • [25] Factors associated with decreased relative dose intensity in older adults with early-stage breast cancer receiving chemotherapy
    Sedrak, Mina S.
    Sun, Can-Lan
    Magnuson, Allison
    Muss, Hyman
    Freedman, Rachel
    Gross, Cary P.
    Tew, William P.
    Klepin, Heidi
    Wildes, Tanya M.
    Dotan, Efrat
    O'Connor, Tracey
    Cohen, Harvey J.
    Kim, Heeyoung
    Katheria, Vani
    Jayani, Reena
    Arsenyan, Anait
    Levi, Abrahm
    Charles, Kemeberly
    Hurria, Arti
    Dale, William
    CANCER RESEARCH, 2020, 80 (04)
  • [26] A PHASE-I AND PHASE-II TRIAL OF TWICE-A-DAY RADIATION COMBINED WITH SIMULTANEOUS CARBOPLATIN CHEMOTHERAPY IN ADVANCED HEAD AND NECK-CANCER
    MUELLER, RP
    STAAR, S
    VOLLING, P
    ACHTERRATH, W
    RADIOLOGY, 1992, 185 : 121 - 121
  • [27] Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial
    Caan, Bette J.
    Brown, Justin C.
    Lee, Catherine
    Binder, Alexandra M.
    Weltzien, Erin
    Ross, Michelle C.
    Quesenberry, Charles P.
    Campbell, Kristin L.
    Feliciano, Elizabeth M. Cespedes
    Castillo, Adrienne
    Quinney, Sara
    Yang, Shengping
    Meyerhardt, Jeffrey A.
    Schmitz, Kathryn H.
    CANCER, 2024, 130 (10) : 1858 - 1868
  • [28] Predictive Factors Associated With Late Pulmonary Toxicity After Definitive Intensity Modulated Radiation Therapy With Induction Chemotherapy for Head and Neck Cancer
    Inokuchi, H.
    Yoshimura, M.
    Hiraoka, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 899 - 899
  • [29] Impact of aprepitant on emesis control, dose intensity (DI) and recurrence free survival (RFS) in head and neck cancer patients (HNC) receiving high dose cisplatin chemotherapy
    Dranitsaris, G.
    Makarenko, S.
    Peixoto, R.
    Cheung, W. Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S755 - S755
  • [30] MODULATION OF THE ANTITUMOR EFFECT OF METHOTREXATE BY LOW-DOSE LEUCOVORIN IN SQUAMOUS-CELL HEAD AND NECK-CANCER - A RANDOMIZED PLACEBO-CONTROLLED CLINICAL-TRIAL
    BROWMAN, GP
    GOODYEAR, MDE
    LEVINE, MN
    RUSSELL, R
    ARCHIBALD, SD
    YOUNG, JEM
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) : 203 - 208
12345